Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.

Innocenti I, Morelli F, Autore F, Tomasso A, Corbingi A, Bellesi S, Za T, De Stefano V, Laurenti L.

Leuk Lymphoma. 2019 May 20:1-3. doi: 10.1080/10428194.2019.1612063. [Epub ahead of print] No abstract available.

PMID:
31106622
2.

HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia.

Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R.

Cancers (Basel). 2019 Apr 23;11(4). pii: E575. doi: 10.3390/cancers11040575.

3.

Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.

Autore F, Innocenti I, Morelli F, Sorà F, Corbingi A, Fianchi L, Criscuolo M, Pagano L, Sica S, Laurenti L.

Hematol Oncol. 2019 Apr 24. doi: 10.1002/hon.2623. [Epub ahead of print] No abstract available.

PMID:
31017684
4.

HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.

Innocenti I, Morelli F, Autore F, Corbingi A, Pasquale R, Sorà F, Pompili M, Laurenti L.

Leuk Lymphoma. 2019 May;60(5):1340-1342. doi: 10.1080/10428194.2018.1523401. Epub 2019 Feb 7. No abstract available.

PMID:
30730231
5.

Unrelated cord blood transplantation and post-transplant cyclophosphamide.

Bacigalupo A, Sica S, Laurenti L, Sora' F, Giammarco S, Metafuni E, Innocenti I, Autore F, Teofili L, Bianchi M, Chiusolo P.

Haematologica. 2019 Feb;104(2):e77-e78. doi: 10.3324/haematol.2018.202598. Epub 2018 Dec 20. No abstract available.

6.

Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.

Autore F, Chiusolo P, Sorà F, Giammarco S, Laurenti L, Innocenti I, Metafuni E, Piccirillo N, Pagano L, Bacigalupo A, Leone G, Sica S.

Leuk Lymphoma. 2019 May;60(5):1328-1330. doi: 10.1080/10428194.2018.1522436. Epub 2018 Dec 11. No abstract available.

PMID:
30526180
7.

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.

Autore F, Strati P, Laurenti L, Ferrajoli A.

Haematologica. 2018 Jun;103(6):931-938. doi: 10.3324/haematol.2017.186684. Epub 2018 May 10. Review.

8.

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.

Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, Martin-Fernandez ML, Cameron A, Fraternali F, Ng T, Parker PJ.

Elife. 2018 May 1;7. pii: e32271. doi: 10.7554/eLife.32271.

9.

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L.

Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. [Epub ahead of print]

PMID:
29602219
10.

Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.

Innocenti I, Rossi D, Trapè G, Autore F, Larocca LM, Gomes V, Cerri M, Falcucci P, Sica S, Gaidano G, Laurenti L.

Hematol Oncol. 2018 Feb 27. doi: 10.1002/hon.2502. [Epub ahead of print]

PMID:
29484684
11.

Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.

Alberelli MA, Innocenti I, Autore F, Laurenti L, De Candia E.

Haematologica. 2018 Mar;103(3):e119-e122. doi: 10.3324/haematol.2017.179044. Epub 2017 Dec 14. No abstract available.

12.

Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.

Innocenti I, Autore F, Pasquale R, Morelli F, Efremov DG, Laurenti L.

Expert Rev Hematol. 2017 Dec;10(12):1069-1076. doi: 10.1080/17474086.2017.1398642. Epub 2017 Nov 3. Review.

PMID:
29082795
13.

Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome.

Autore F, Innocenti I, Luigetti M, Piccirillo N, Sora F, Chiusolo P, Sica S, Bacigalupo A, Laurenti L.

Hematol Oncol. 2018 Apr;36(2):392-398. doi: 10.1002/hon.2478. Epub 2017 Sep 15. Review.

PMID:
28913957
14.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

15.

Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Sorà F, Ponziani FR, Laurenti L, Chiusolo P, Autore F, Gasbarrini A, Sica S, Pompili M.

Leuk Lymphoma. 2017 Apr;58(4):993-995. doi: 10.1080/10428194.2016.1219906. Epub 2016 Aug 22. No abstract available.

PMID:
27546591
16.

Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia.

Sorà F, Chiusolo P, Laurenti L, Autore F, Giammarco S, Sica S.

Mediterr J Hematol Infect Dis. 2016 Jul 1;8(1):e2016027. doi: 10.4084/MJHID.2016.027. eCollection 2016.

17.

N-terminal nesprin-2 variants regulate β-catenin signalling.

Zhang Q, Minaisah RM, Ferraro E, Li C, Porter LJ, Zhou C, Gao F, Zhang J, Rajgor D, Autore F, Shanahan CM, Warren DT.

Exp Cell Res. 2016 Jul 15;345(2):168-79. doi: 10.1016/j.yexcr.2016.06.008. Epub 2016 Jun 16.

18.

Identification and Validation of Putative Nesprin Variants.

Autore F, Shanahan CM, Zhang Q.

Methods Mol Biol. 2016;1411:211-20. doi: 10.1007/978-1-4939-3530-7_13.

PMID:
27147044
19.

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.

Laurenti L, Innocenti I, Autore F, Sica S, Efremov DG.

Onco Targets Ther. 2016 Jan 20;9:421-9. doi: 10.2147/OTT.S72845. eCollection 2016. Review.

20.

Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.

Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P, Bellesi S, Efremov DG, Sica S, Mauro FR.

Leuk Lymphoma. 2016 Oct;57(10):2429-31. doi: 10.3109/10428194.2015.1137293. Epub 2016 Jan 27. No abstract available.

PMID:
26818825
21.

Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units.

Salvi G, Innocenti I, Autore F, Laurenti L.

Mediterr J Hematol Infect Dis. 2015 Nov 1;7(1):e2015056. doi: 10.4084/MJHID.2015.056. eCollection 2015.

22.

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, Del Poeta G, Mauro FR, Cortelezzi A, Borza PA, Ghio F, Mondello P, Murru R, Gozzetti A, Cariccio MR, Piccirillo N, Boncompagni R, Cantonetti M, Principe MI, Reda G, Bongarzoni V, Cervetti G, Pitini V, Foà R, Sica S, D'Arena G.

Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.

PMID:
26307523
23.

Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience.

Laurenti L, Autore F, Innocenti I, Vannata B, Piccirillo N, Sorà F, Speziale D, Pompili M, Efremov D, Sica S.

Leuk Lymphoma. 2015;56(10):2841-6. doi: 10.3109/10428194.2015.1017822. Epub 2015 Mar 14.

PMID:
25682966
24.

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.

Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R.

Leukemia. 2015 Jun;29(6):1360-5. doi: 10.1038/leu.2015.21. Epub 2015 Feb 4.

PMID:
25650091
25.

Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.

Iacovelli S, Hug E, Bennardo S, Duehren-von Minden M, Gobessi S, Rinaldi A, Suljagic M, Bilbao D, Bolasco G, Eckl-Dorna J, Niederberger V, Autore F, Sica S, Laurenti L, Wang H, Cornall RJ, Clarke SH, Croce CM, Bertoni F, Jumaa H, Efremov DG.

Blood. 2015 Mar 5;125(10):1578-88. doi: 10.1182/blood-2014-07-587790. Epub 2015 Jan 6.

26.

Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.

Veronese A, Pepe F, Chiacchia J, Pagotto S, Lanuti P, Veschi S, Di Marco M, D'Argenio A, Innocenti I, Vannata B, Autore F, Marchisio M, Wernicke D, Verginelli F, Leone G, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R.

Leukemia. 2015 Jan;29(1):86-95. doi: 10.1038/leu.2014.139. Epub 2014 Apr 15.

27.

Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Sorà F, Autore F, Chiusolo P, Marietti S, Bayer J, Laurenti L, Giammarco S, Ausoni G, Leone G, Sica S.

Leuk Lymphoma. 2014 Dec;55(12):2958-60. doi: 10.3109/10428194.2014.909038. Epub 2014 May 6. No abstract available.

PMID:
24684229
28.

Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome.

De Padua L, Laurenti L, Falcucci P, D'arena G, Vannata B, Innocenti I, Autore F, Piccirillo N, Za T, Marietti S, Efremov DG, Sica S.

Ann Hematol. 2014 Jul;93(7):1261-2. doi: 10.1007/s00277-013-1968-x. Epub 2013 Dec 5. No abstract available.

PMID:
24306088
29.

Large-scale modelling of the divergent spectrin repeats in nesprins: giant modular proteins.

Autore F, Pfuhl M, Quan X, Williams A, Roberts RG, Shanahan CM, Fraternali F.

PLoS One. 2013 May 6;8(5):e63633. doi: 10.1371/journal.pone.0063633. Print 2013.

30.

Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience.

Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Piccirillo N, Za T, Bellesi S, Marietti S, Sica S, Efremov DG, Leone G.

Mediterr J Hematol Infect Dis. 2013 May 2;5(1):e2013031. doi: 10.4084/MJHID.2013.031. Print 2013.

31.

The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Sica S, Efremov DG.

Mediterr J Hematol Infect Dis. 2013 Apr 10;5(1):e2013027. doi: 10.4084/MJHID.2013.027. Print 2013.

32.

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia.

Vannata B, Innocenti I, Autore F, Sorà F, Chiusolo P, Leone G, Sica S, Laurenti L.

Am J Hematol. 2012 Dec;87(12):E133. doi: 10.1002/ajh.23349. Epub 2012 Oct 31. No abstract available.

33.

B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia.

Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, Tuana G, Lionetti M, Guercini N, Novella E, Nichele I, Montaldi A, Autore F, Gregorini A, Barcellini W, Callea V, Mauro FR, Laurenti L, Foà R, Neri A, Rodeghiero F, Cortelezzi A.

Am J Hematol. 2013 Jan;88(1):32-6. doi: 10.1002/ajh.23342. Epub 2012 Oct 31.

34.

Multiple novel nesprin-1 and nesprin-2 variants act as versatile tissue-specific intracellular scaffolds.

Rajgor D, Mellad JA, Autore F, Zhang Q, Shanahan CM.

PLoS One. 2012;7(7):e40098. doi: 10.1371/journal.pone.0040098. Epub 2012 Jul 2.

35.

Protein-water interactions in MD simulations: POPS/POPSCOMP solvent accessibility analysis, solvation forces and hydration sites.

Fornili A, Autore F, Chakroun N, Martinez P, Fraternali F.

Methods Mol Biol. 2012;819:375-92. doi: 10.1007/978-1-61779-465-0_23.

PMID:
22183548
36.

In silico phosphorylation of the autoinhibited form of p47(phox): insights into the mechanism of activation.

Autore F, Pagano B, Fornili A, Rittinger K, Fraternali F.

Biophys J. 2010 Dec 1;99(11):3716-25. doi: 10.1016/j.bpj.2010.09.008.

37.

Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations.

Autore F, Bergeron JR, Malim MH, Fraternali F, Huthoff H.

PLoS One. 2010 Jul 12;5(7):e11515. doi: 10.1371/journal.pone.0011515.

38.

Mutation of the RAD51C gene in a Fanconi anemia-like disorder.

Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG.

Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.

PMID:
20400963
39.

RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.

Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH.

PLoS Pathog. 2009 Mar;5(3):e1000330. doi: 10.1371/journal.ppat.1000330. Epub 2009 Mar 6.

40.

The Pleurotus ostreatus laccase multi-gene family: isolation and heterologous expression of new family members.

Pezzella C, Autore F, Giardina P, Piscitelli A, Sannia G, Faraco V.

Curr Genet. 2009 Feb;55(1):45-57. doi: 10.1007/s00294-008-0221-y. Epub 2008 Nov 26.

PMID:
19034452
41.

Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax.

Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV.

Nucleic Acids Res. 2008 Sep;36(16):5139-51. doi: 10.1093/nar/gkn490. Epub 2008 Aug 2.

42.

The cold-active Lip1 lipase from the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125 is a member of a new bacterial lipolytic enzyme family.

de Pascale D, Cusano AM, Autore F, Parrilli E, di Prisco G, Marino G, Tutino ML.

Extremophiles. 2008 May;12(3):311-23. doi: 10.1007/s00792-008-0163-9. Epub 2008 Apr 24.

PMID:
18437283
43.

Development of new laccases by directed evolution: functional and computational analyses.

Festa G, Autore F, Fraternali F, Giardina P, Sannia G.

Proteins. 2008 Jul;72(1):25-34. doi: 10.1002/prot.21889.

PMID:
18186469
44.

Structural characterization of heterodimeric laccases from Pleurotus ostreatus.

Giardina P, Autore F, Faraco V, Festa G, Palmieri G, Piscitelli A, Sannia G.

Appl Microbiol Biotechnol. 2007 Jul;75(6):1293-300. Epub 2007 Apr 12.

PMID:
17429621
45.

Interaction of malaria parasite-inhibitory antibodies with the merozoite surface protein MSP1(19) by computational docking.

Autore F, Melchiorre S, Kleinjung J, Morgan WD, Fraternali F.

Proteins. 2007 Feb 15;66(3):513-27.

PMID:
17173281
46.

The thiol-disulfide oxidoreductase system in the cold-adapted bacterium Pseudoalteromonas haloplanktis TAC 125: discovery of a novel disulfide oxidoreductase enzyme.

Madonna S, Papa R, Birolo L, Autore F, Doti N, Marino G, Quemeneur E, Sannia G, Tutino ML, Duilio A.

Extremophiles. 2006 Feb;10(1):41-51. Epub 2005 Sep 23.

PMID:
16179963

Supplemental Content

Loading ...
Support Center